Chimerix (NASDAQ:CMRX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Chimerix (NASDAQ:CMRX – Get Rating) from a sell rating to a hold rating in a research note issued to investors on Friday.

Several other equities analysts have also commented on CMRX. Zacks Investment Research lowered Chimerix from a hold rating to a strong sell rating in a research note on Thursday, March 3rd. HC Wainwright reaffirmed a buy rating and issued a $24.00 price target (up previously from $21.00) on shares of Chimerix in a research note on Wednesday, December 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Buy and an average price target of $15.75.

Shares of NASDAQ:CMRX opened at $4.65 on Friday. The business has a fifty day moving average of $5.36 and a two-hundred day moving average of $5.78. The stock has a market cap of $404.68 million, a P/E ratio of -2.24 and a beta of 1.34. Chimerix has a 52-week low of $4.56 and a 52-week high of $9.29.

Chimerix (NASDAQ:CMRX – Get Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.34). Chimerix had a negative net margin of 8,753.71% and a negative return on equity of 84.90%. The business had revenue of $0.05 million during the quarter, compared to analyst estimates of $45.06 million. During the same period last year, the company earned ($0.19) EPS. Analysts predict that Chimerix will post -0.11 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of CMRX. Marshall Wace LLP acquired a new position in Chimerix during the 1st quarter worth about $166,000. Morgan Stanley increased its holdings in Chimerix by 55.2% during the 2nd quarter. Morgan Stanley now owns 49,277 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 17,533 shares during the period. Parametric Portfolio Associates LLC increased its holdings in Chimerix by 26.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 22,684 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 4,805 shares during the period. PAX Financial Group LLC purchased a new stake in Chimerix during the 3rd quarter worth about $198,000. Finally, SG Americas Securities LLC purchased a new stake in Chimerix during the 3rd quarter worth about $204,000. 63.38% of the stock is currently owned by hedge funds and other institutional investors.

About Chimerix (Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

See Also